12 January 2021 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Non-Pancreatic Neuroendocrine Tumors. View PDF
Recent News KHP Kent and Hampshire Hospitals NET Centre Twelfth Annual Meeting News from Neuroendocrine Cancer UK Theragnostics in Neuroendocrine Neoplasms Webinar – register now! YDEF-UKINETS Virtual NETS Training Meeting Grant and Prize Winners announced at UKINETS Conference 2024
Sign up for our newsletterSign-up for our email newsletter. Simply give us your email address in the box below to sign-up.Email Close GDPR Cookie Settings Privacy Overview Strictly Necessary Cookies 3rd Party Cookies Powered by GDPR Cookie Compliance Privacy Overview This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Strictly Necessary Cookies Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. Enable or Disable Cookies Enabled Disabled If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again. 3rd Party Cookies This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website. Enable or Disable Cookies Enabled Disabled Please enable Strictly Necessary Cookies first so that we can save your preferences!
